Compare RBBN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | IMMX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 528.0M |
| IPO Year | 2017 | 2021 |
| Metric | RBBN | IMMX |
|---|---|---|
| Price | $2.62 | $8.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.67 | ★ $19.20 |
| AVG Volume (30 Days) | ★ 1.0M | 627.7K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | $10.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $1.87 |
| 52 Week High | $4.29 | $11.61 |
| Indicator | RBBN | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 46.25 |
| Support Level | $2.05 | $8.00 |
| Resistance Level | $2.93 | $8.97 |
| Average True Range (ATR) | 0.17 | 0.66 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 41.67 | 28.86 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.